Atricure announces launch of cryosphere max™ probe for post-operative pain management

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management, and post-operative pain management, today announced that it has launched the cryosphere max™ cryoablation probe. the cryosphere max probe features a larger ball tip designed to optimize cryo nerve block™ therapy (cryonb). the new probe reduces freeze times by 50% when compared to atricure's first generation.
ATRC Ratings Summary
ATRC Quant Ranking